DTU
DTU

Trial Evaluating Cardiovascular Outcomes With Sitagliptin

Conference abstracts (9 of 30)

Years :

Search conference abstracts :

2016

52nd Annual Meeting of the European Association for the Study of Diabetes, Munich
Sitagliptin and risk of fractures in type 2 diabetes: results from the TECOS trial
R.G. Josse, S.R. Majumdar, Y. Zheng, J.B. Buse, J.B. Green, K.D. Kaufman, E.D. Peterson, R.R.Holman, P.W. Armstrong, on behalf of the TECOS Study Group
Diabetologia 2016;59:Suppl 1:S372
[Abstract]

52nd Annual Meeting of the European Association for the Study of Diabetes, Munich
Impact of sitagliptin on cardiovascular and safety-related outcomes in insulin-treated type 2 diabetes: the TECOS experience
M.A. Bethel, S.S. Engel, J. Ding, R.G. Josse, R.R. Holman and the TECOS Study Group
Diabetologia 2016;59:Suppl 1:S369
[Abstract]

52nd Annual Meeting of the European Association for the Study of Diabete, Munich
Assessing the safety of sitagliptin in patients with type 2 diabetes and chronic kidney disease in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS)
S.S. Engel, S. Suryawanshi, R.G. Josse, E.D. Peterson, R.R. Holman and the TECOS Study Group
Diabetologia 2016;59:Suppl 1:S361
[Abstract]

52nd Annual Meeting of the European Association for the Study of Diabetes, Munich
Estimated 10-year benefit for diabetes complication rates by 1% HbA1c decrements in people with type 2 diabetes and cardiovascular disease
S.A. Mostafa, R.R. Holman, R.L. Coleman, O. Agbaje, M.A. Bethel
Diabetologia 2016;59:Suppl 1:S543
[Abstract]

52nd Annual Meeting of the European Association for the Study of Diabetes, Munich
Sex differences in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS)
J.B. Green, J. Alfredsson, S.R. Stevens, S.D. Reed, D.K. McGuire, P.W. Armstrong, S.S. Engel, M.A. Bethel, F. Van de Werf, E.D. Peterson, R.R. Holman
Diabetologia 2016;59:Suppl 1:S544
[Abstract]

American Heart Association (AHA) Scientific Sessions 2016, New Orleans
Treated Systolic Blood Pressure and Cardiovascular Risk in Adults With Hypertension and Type 2 Diabetes: Results From the TECOS Trial
Ann M Navar, Dianne S Gallup, Yuliya Lokhnygina, Jennifer B Green, Darren K McGuire, Paul W Armstrong, John B Buse, Samuel S Engel, John M Lachin, Eberhard Standl, Frans Van de Werf, Rury R Holman, and Eric D Peterson
Circulation 2016;134:Suppl 1:
[Abstract]

Diabetes UK Annual Professional Conference, Glasgow
Assessing the safety of sitagliptin in elderly participants in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin
MA Bethel, SS Engel, JB Green, Z Huang, KD Kaufman,E Standl, S Suryawanshi, F Van de Werf, ED Peterson, and RR Holman
Diabetic Medicine 2016;33:Suppl 1:86
[Abstract]

American Diabetes Association (ADA) Conference, New Orleans
Assessing the Safety of Sitagliptin in Patients with Type 2 Diabetes and Chronic Kidney Disease in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS)
SAMUEL S ENGEL, SHAILAJA SURYAWANSHI, ROBERT G JOSSE, ERIC PETERSON, RURY R HOLMAN, TECOS STUDY GROUP
Diabetes 2016;65:(Suppl 1):1181-P
[Abstract]

American Diabetes Association (ADA) Conference, New Orleans
Sitagliptin and Risk of Fractures in Type 2 Diabetes: Results from the TECOS Trial
ROBERT G JOSSE, SUMIT R MAJUMDAR, JOHN B BUSE, JENNIFER B GREEN, KEITH D KAUFMAN, CYNTHIA M WESTERHOUT, YINGGAN ZHENG, ERIC PETERSON, RURY R HOLMAN, PAUL W ARMSTRONG, TECOS STUDY GROUP
Diabetes 2016;65:(Suppl 1):587-P
[Abstract]